Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-671 and Allopurinol DDI Study in Gout Patients
NCT07367971Phase 1Completed
- Sponsor
- Atom Therapeutics
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lingdolinurad in gout, sponsored by Atom Therapeutics. Primary endpoints: Maximum plasma concentration of allopurinol at Day 21 and Area under the plasma concentration-time curve over the dosing interval of allopurinol at Day 21. Started Jan 2026; status: completed.
02
Drugs
lingdolinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT07367971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367971.